4 búsqueda de la palabra clave 'bevacizumab'

Telangiectasia hemorrágica hereditaria. Síndrome de Osler Weber Rendú y manejo con bevacizumab / Juan Felipe Combariza Vallejo ; Viviana Patricia Olaya Colorado  

Público ISBD Título : Telangiectasia hemorrágica hereditaria. Síndrome de Osler Weber Rendú y manejo con bevacizumab Otros títulos : Hereditary hemorrhagic telangiectasia. Osler Weber Rendu syndrome and management with bevacizumab Tipo de documento : documento electrónico Autores : Juan Felipe Combariza Vallejo, ; Viviana Patricia Olaya Colorado, Fecha de publicación : 2015 Títulos uniformes : Acta Médica Colombiana Idioma : Español (spa) Palabras clave : telangiectasia hemorrágica hereditaria  síndrome de Osler Weber Rendu  bevacizumab  malformaciones arteriovenosas Resumen : Presentamos un caso clínico de una paciente con diagnóstico de telangiectasia hemorrágica hereditaria con múltiples manifestaciones sistémicas debidas a sangrados profusos, anemia severa y malformaciones arteriovenosas pulmonares, hepáticas y falla cardiaca de alto débito, con adecuada respuesta al uso de bevacizumab. Mención de responsabilidad : Juan Felipe Combariza, Viviana Patricia Olaya Referencia : Acta méd. colomb ; 40(1): 66-68, ene.-mar. 2015. En línea : http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-244820150001000 [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4983 Telangiectasia hemorrágica hereditaria. Síndrome de Osler Weber Rendú y manejo con bevacizumab = Hereditary hemorrhagic telangiectasia. Osler Weber Rendu syndrome and management with bevacizumab [documento electrónico] / Juan Felipe Combariza Vallejo, ; Viviana Patricia Olaya Colorado,  . - 2015. Obra : Acta Médica Colombiana Idioma : Español (spa) Palabras clave : telangiectasia hemorrágica hereditaria  síndrome de Osler Weber Rendu  bevacizumab  malformaciones arteriovenosas Resumen : Presentamos un caso clínico de una paciente con diagnóstico de telangiectasia hemorrágica hereditaria con múltiples manifestaciones sistémicas debidas a sangrados profusos, anemia severa y malformaciones arteriovenosas pulmonares, hepáticas y falla cardiaca de alto débito, con adecuada respuesta al uso de bevacizumab. Mención de responsabilidad : Juan Felipe Combariza, Viviana Patricia Olaya Referencia : Acta méd. colomb ; 40(1): 66-68, ene.-mar. 2015. En línea : http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-244820150001000 [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4983

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001542	AC-2015-135	Archivo digital	Producción Científica	Artículos científicos	Disponible

Treatment of aggressive pituitary adenomas and carcinomas – an overview / Luis Vicente Syro Moreno  

Público ISBD Título : Treatment of aggressive pituitary adenomas and carcinomas – an overview Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : European Neurological Review Idioma : Inglés (eng) Palabras clave : Pituitary adenoma  pituitary carcinoma  O6-methylguanine-DNA methyltransferase (MGMT)  temozolomide  everolimus  bevacizumab Resumen : Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumours, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumours and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumours are also discussed. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Fabio Rotondo, Humberto Uribe, Luis C Penagos, Eva Horvath, Kalman Kovacs Referencia : European Neurological Review. 2012;7(3):178–80. DOI (Digital Object Identifier) : 10.17925/ENR.2012.07.03.178 En línea : https://touchneurology.com/treatment-of-aggressive-pituitary-adenomas-and-carcin [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3630 Treatment of aggressive pituitary adenomas and carcinomas – an overview [documento electrónico] / Luis Vicente Syro Moreno,  . - 2012. Obra : European Neurological Review Idioma : Inglés (eng) Palabras clave : Pituitary adenoma  pituitary carcinoma  O6-methylguanine-DNA methyltransferase (MGMT)  temozolomide  everolimus  bevacizumab Resumen : Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumours, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumours and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumours are also discussed. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Fabio Rotondo, Humberto Uribe, Luis C Penagos, Eva Horvath, Kalman Kovacs Referencia : European Neurological Review. 2012;7(3):178–80. DOI (Digital Object Identifier) : 10.17925/ENR.2012.07.03.178 En línea : https://touchneurology.com/treatment-of-aggressive-pituitary-adenomas-and-carcin [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3630

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000200	AC-2012-040	Archivo digital	Producción Científica	Artículos científicos	Disponible

Treatment of aggressive pituitary adenomas and carcinomas-An overview / Luis Vicente Syro Moreno  

Público ISBD Título : Treatment of aggressive pituitary adenomas and carcinomas-An overview Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : US Endocrinology Idioma : Inglés (eng) Palabras clave : Pituitary adenoma  pituitary carcinoma  O6-methylguanine-DNA methyltransferase (MGMT)  temozolomide  everolimus  bevacizumab Resumen : Most pituitary tumors are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumors, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation, and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumors and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumors are also discussed. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Fabio Rotondo, Humberto Uribe, Luis C Penagos, Eva Horvath, Kalman Kovacs DOI (Digital Object Identifier) : 10.17925/USE.2012.08.01.50 En línea : https://www.touchendocrinology.com/treatment-of-aggressive-pituitary-adenomas-an [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4505 Treatment of aggressive pituitary adenomas and carcinomas-An overview [documento electrónico] / Luis Vicente Syro Moreno,  . - 2012. Obra : US Endocrinology Idioma : Inglés (eng) Palabras clave : Pituitary adenoma  pituitary carcinoma  O6-methylguanine-DNA methyltransferase (MGMT)  temozolomide  everolimus  bevacizumab Resumen : Most pituitary tumors are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumors, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation, and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumors and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumors are also discussed. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Fabio Rotondo, Humberto Uribe, Luis C Penagos, Eva Horvath, Kalman Kovacs DOI (Digital Object Identifier) : 10.17925/USE.2012.08.01.50 En línea : https://www.touchendocrinology.com/treatment-of-aggressive-pituitary-adenomas-an [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4505

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001004	AC-2012-093	Archivo digital	Producción Científica	Artículos científicos	Disponible

Anti-VEGF therapy in pituitary carcinoma / Luis Vicente Syro Moreno  

Público ISBD Título : Anti-VEGF therapy in pituitary carcinoma Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2011 Títulos uniformes : Pituitary Idioma : Inglés (eng) Palabras clave : Pituitary carcinoma  angiogenesis inhibitors  vascular endothelial growth factor-A  bevacizumab  temozolomide Resumen : We report the case of a 44-year-old male patient with an aggressive silent corticotroph cell pituitary adenoma, subtype 2. In that it progressed to carcinoma despite temozolomide administration, anti-VEGF therapy was begun. MRI, PET scan and pathologic analysis were undertaken. After 10 months of anti-VEGF (bevacizumab) treatment no progression of the lesion was noted. The tumor was biopsied and morphological analysis showed severe cell injury, vascular abnormalities and fibrosis. Bevacizumab treatment has continued for additional 16 months to present with stabilization of disease as documented on serial MRI and PET scans. This is the first case of a bevacizumab-treated pituitary carcinoma with long-term, now 26 months, control of disease. The present findings are promising in that anti-angiogenic therapy appears to represent a new option in the treatment of aggressive pituitary tumors. Mención de responsabilidad : Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Ayca Ersen, Humberto Uribe, Camilo E Fadul, Fabio Rotondo, Eva Horvath, Kalman Kovacs Referencia : Pituitary. 2012 Sep;15(3):445-9. DOI (Digital Object Identifier) : 10.1007/s11102-011-0346-8 PMID : 21918831 En línea : https://link.springer.com/article/10.1007%2Fs11102-011-0346-8 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3568 Anti-VEGF therapy in pituitary carcinoma [documento electrónico] / Luis Vicente Syro Moreno,  . - 2011. Obra : Pituitary Idioma : Inglés (eng) Palabras clave : Pituitary carcinoma  angiogenesis inhibitors  vascular endothelial growth factor-A  bevacizumab  temozolomide Resumen : We report the case of a 44-year-old male patient with an aggressive silent corticotroph cell pituitary adenoma, subtype 2. In that it progressed to carcinoma despite temozolomide administration, anti-VEGF therapy was begun. MRI, PET scan and pathologic analysis were undertaken. After 10 months of anti-VEGF (bevacizumab) treatment no progression of the lesion was noted. The tumor was biopsied and morphological analysis showed severe cell injury, vascular abnormalities and fibrosis. Bevacizumab treatment has continued for additional 16 months to present with stabilization of disease as documented on serial MRI and PET scans. This is the first case of a bevacizumab-treated pituitary carcinoma with long-term, now 26 months, control of disease. The present findings are promising in that anti-angiogenic therapy appears to represent a new option in the treatment of aggressive pituitary tumors. Mención de responsabilidad : Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Ayca Ersen, Humberto Uribe, Camilo E Fadul, Fabio Rotondo, Eva Horvath, Kalman Kovacs Referencia : Pituitary. 2012 Sep;15(3):445-9. DOI (Digital Object Identifier) : 10.1007/s11102-011-0346-8 PMID : 21918831 En línea : https://link.springer.com/article/10.1007%2Fs11102-011-0346-8 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3568

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000137	AC-2011-022	Archivo digital	Producción Científica	Artículos científicos	Disponible